Exelixis, Inc. (EXEL)
NASDAQ: EXEL · Real-Time Price · USD
64.63
-1.20 (-1.82%)
At close: Nov 20, 2026, 4:00 PM EST
63.57
-1.06 (-1.64%)
After-hours: Nov 20, 2026, 7:30 PM EST
Exelixis Revenue
Exelixis had revenue of $658.70M in the quarter ending September 30, 2026, with 10.19% growth. This brings the company's total for the last twelve months to $2.50B, up 9.12% year-over-year. In the year 2025, Exelixis had annual revenue of $2.32B with 6.98% growth. That makes Exelixis the 4,319th largest company in the world by revenue and 1,172nd in the United States.
Revenue (ttm)
$2.50B
Revenue Growth
+9.12%
P/S Ratio
6.32
Revenue / Employee
$2,318,348
Employees
1,077
Market Cap
15.77B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Exelixis breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.32B | 151.43M | 6.98% |
| Dec 31, 2024 | 2.17B | 338.49M | 18.49% |
| Dec 31, 2023 | 1.83B | 219.15M | 13.60% |
| Dec 31, 2022 | 1.61B | 176.09M | 12.27% |
| Dec 31, 2021 | 1.43B | 447.43M | 45.31% |
| Dec 31, 2020 | 987.54M | 19.76M | 2.04% |
| Dec 31, 2019 | 967.78M | 113.95M | 13.35% |
| Dec 31, 2018 | 853.83M | 401.35M | 88.70% |
| Dec 31, 2017 | 452.48M | 261.02M | 136.34% |
| Dec 31, 2016 | 191.45M | 154.28M | 415.05% |
| Dec 31, 2015 | 37.17M | 12.06M | 48.03% |
| Dec 31, 2014 | 25.11M | -6.23M | -19.87% |
| Dec 31, 2013 | 31.34M | -16.11M | -33.96% |
| Dec 31, 2012 | 47.45M | -242.19M | -83.62% |
| Dec 31, 2011 | 289.64M | 104.59M | 56.52% |
| Dec 31, 2010 | 185.05M | 33.29M | 21.93% |
| Dec 31, 2009 | 151.76M | 33.90M | 28.76% |
| Dec 31, 2008 | 117.86M | 4.39M | 3.87% |
| Dec 31, 2007 | 113.47M | 14.80M | 15.00% |
| Dec 31, 2006 | 98.67M | 22.71M | 29.90% |
| Dec 31, 2005 | 75.96M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Incyte | 6.01B |
| Alnylam Pharmaceuticals | 5.01B |
| Jazz Pharmaceuticals | 4.72B |
| BioMarin Pharmaceutical | 3.66B |
| BioNTech SE | 2.75B |
| Halozyme Therapeutics | 1.80B |
| Insmed | 1.52B |
| Ascendis Pharma | 1.37B |
EXEL News
- 3 days ago - Exelixis Transcript: Jefferies Global Healthcare Conference - Transcripts
- 4 days ago - Exelixis Transcript: UBS Global Biopharma Conference 2026 - Transcripts
- 8 days ago - Exelixis price target lowered to $57 from $60 at Morgan Stanley - TheFly
- 10 days ago - Exelixis Transcript: Stifel 2026 Healthcare Conference 2026 - Transcripts
- 11 days ago - Exelixis Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 17 days ago - Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November - Business Wire
- 19 days ago - Exelixis price target raised to $78 from $56 at H.C. Wainwright - TheFly
- 22 days ago - Exelixis price target raised to $60 from $53 at Morgan Stanley - TheFly